| HELPFUL LINKS | |||||||||
 |
Monthly Calendar Topics |
|
Find A Hospital |
|
Find A Doctor | 
|
Medical Careers | ||
New therapy eliminates deadly leukemia stem cells
The following information is provided by a third party and has not been edited by The Post and Courier for content or accuracy.
(Ivanhoe Newswire) -- A recent study describes a novel therapeutic approach which significantly advances the fight against the deadly human acute myeloid leukemia (AML), a notoriously treatment-resistant blood cancer.
AML is a cancer of the white blood cells that has an extremely poor prognosis and does not respond well to conventional chemotherapy. "The cellular and molecular basis for this dismal picture is unclear," senior study author Associate Professor Richard Lock from the Children's Cancer Institute Australia and the University of New South Wales is quoted as saying. "However, previous research has suggested that leukemia stem cells (LSCs) may lie at the heart of post-treatment relapse and chemoresistance."
Associate Professor Lock and colleagues exploited the fact that the molecule CD123 is expressed at very high levels on LSCs but not on normal blood cells. The researchers created a therapeutic antibody called 7G3 that recognized and bound to CD123, hoping this antibody would selectively interfere with AML-LSC survival.
When AML-LSCs from human patients were transplanted into mice treated with the 7G3 antibody, signaling for growth and proliferation in the tumor cells was blocked. Further, the antibody impaired migration of the AML-LSCs to bone marrow and activated the innate immune system of the host mouse to destroy the AML-LSCs. Overall, treatment with 7G3 antibody substantially improved mouse survival when compared with control groups.
The researchers go on to report that a CD123-targeting antibody is currently being used in phase 1 clinical trials of advanced AML and that there are no signs of treatment-related toxicity. These results hold great promise for future cancer therapeutics.
Associate Professor Lock concluded, "The recent characterization of defined populations of cancer stem cells in a range of human malignancies, as well as their relative resistance to conventional chemotherapy and radiotherapy, supports the broad applicability of our approach and provides rationale for the progression . . . from preclinical evaluation to clinical trials."
SOURCE:Cell Stem Cell, July 2, 2009
E-mail this story
Printer-friendly version
Comments
Use the comment form below to begin a discussion about this content.
Notice about comments:Postandcourier.com is pleased to offer readers the enhanced ability to comment on stories. We expect our readers to engage in lively, yet civil discourse. Postandcourier.com does not edit user submitted statements and we cannot promise that readers will not occasionally find offensive or inaccurate comments posted in the comments area. Responsibility for the statements posted lies with the person submitting the comment, not postandcourier.com. If you find a comment that is objectionable, please click "report abuse" and we will review it for possible removal. Please be reminded, however, that in accordance with our Terms of Use and federal law, we are under no obligation to remove any third party comments posted on our website.
Users can now build user-to-user connections, follow friends' recent posts, add an avatar that fits their personality, and more. If you have posted here before you'll need to sign up again, or if you've never posted before, start now by signing up!
Full terms and conditions can be read here.